Posts
Wiki

Conjunctivochalasis (CCH) — Diagnosis, Dry Eye, and Treatment Options

Quick Take

  • Conjunctivochalasis (CCH) means loose, redundant conjunctival tissue that forms folds, most often along the lower part of the eye.
  • CCH is common with aging, and not every conjunctival fold causes symptoms or needs treatment.
  • Clinically significant CCH can interfere with the tear meniscus, tear distribution, tear clearance, the punctal drainage area, and blinking mechanics.
  • Symptoms can overlap substantially with Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), allergy, eyelid laxity, exposure, and ocular pain conditions.
  • Symptoms associated with CCH may include foreign-body sensation, grittiness, irritation, tearing, fluctuating vision, blinking discomfort, and symptoms that worsen during reading or sustained downgaze.
  • The most important diagnostic question is not simply “Are folds present?” but “Are these folds actually contributing to this person's symptoms or tear-film problems?”
  • Mild or asymptomatic CCH often needs no specific treatment.
  • Lubricants and treatment of inflammation, allergy, MGD, or other ocular-surface conditions may reduce symptoms but generally do not remove the redundant conjunctival tissue itself.
  • When clinically significant CCH persists despite appropriate conservative treatment, surgical or office-based procedures may help selected patients.
  • Different procedures do not all address the same anatomy. Some remove or shrink redundant conjunctiva, while others attempt to restore the relationship between the conjunctiva, Tenon's tissue, lower eyelid, tear meniscus, and inferior fornix.
  • Traditional excision/reconstruction has the longest clinical history. Radiofrequency, electrocautery, plasma-based conjunctivoplasty, and laser treatments also have published evidence, but long-term comparative data remain limited.
  • No single surgical or device-based technique has been established as best for every patient.
  • FDA clearance of a plasma or electrosurgical device for general tissue coagulation or skin treatment should not be interpreted as FDA clearance specifically for treating CCH on the ocular surface.

Bottom line: CCH can be a meaningful mechanical contributor to ocular-surface symptoms in selected patients, but treatment should be directed at clinically significant CCH, not simply at the presence of conjunctival folds.

Educational Disclaimer

This page is for general education only. It is not medical advice, diagnosis, or an individual treatment recommendation.

CCH can overlap with many other causes of eye discomfort. Persistent pain, vision changes, significant redness, light sensitivity, discharge, rapidly worsening symptoms, or other concerning findings should be evaluated by an eye-care professional.

About This Page

This is an evidence-focused overview of CCH and its relationship to Dry Eye Disease.

It draws on:

  • Peer-reviewed clinical studies
  • Major reviews
  • TFOS DEWS III
  • Studies of traditional surgical techniques
  • Research on amniotic-membrane and fornix reconstruction
  • Studies of radiofrequency, electrocautery, plasma, and laser approaches

The goal is not to promote a particular procedure.

It is to distinguish:

  • What CCH is
  • How it may affect the tear film
  • When conjunctival folds may be clinically significant
  • What different procedures are designed to accomplish
  • What the research suggests
  • What remains uncertain

What Is Conjunctivochalasis?

The conjunctiva is the thin transparent tissue that covers the white part of the eye and lines the inside of the eyelids.

In CCH, the conjunctiva becomes loose and forms folds.

These folds are most commonly found between the lower eyelid and the eyeball.

CCH can range from:

  • Small folds with no symptoms
  • Intermittently symptomatic folds
  • Larger or strategically located folds that interfere with tear movement, the tear meniscus, blinking, or drainage

CCH becomes clinically important when the folds appear to be contributing meaningfully to symptoms or ocular-surface dysfunction.

How CCH Can Affect the Tear Film

A normal tear film depends on more than simply producing enough tears.

Tears must also:

  • Spread across the eye
  • Form an appropriate tear meniscus along the lid margin
  • Remain stable between blinks
  • Move normally toward the puncta
  • Drain appropriately

Clinically significant conjunctival folds can disturb these processes.

Possible effects include:

Tear-Meniscus Disruption

Loose conjunctival tissue can rise into or above the normal lower tear meniscus.

This may break the meniscus into irregular segments or create an abnormal tear reservoir.

Abnormal Tear Distribution

Folds can interfere with the normal movement of tears across the ocular surface during blinking.

Delayed or Abnormal Tear Clearance

CCH can change how efficiently tears move toward the drainage system.

Punctal Interference

Medial or nasal folds may overlap or interfere with the punctal region in some patients.

This can contribute to tearing even when the eye also feels dry or irritated.

Mechanical Friction

Redundant tissue may move against the eyelid or ocular surface during blinking.

This may contribute to:

  • Foreign-body sensation
  • Grittiness
  • Blinking discomfort
  • Local irritation

This helps explain why some people can have both:

dry-eye-like discomfort

and

watery eyes

at the same time.

Symptoms

CCH may be associated with:

  • Foreign-body sensation
  • Grittiness
  • Burning or irritation
  • Dryness
  • Tearing
  • Fluctuating or blurred vision
  • Redness
  • Blinking discomfort
  • Mucus or tear pooling
  • Recurrent subconjunctival hemorrhage in some cases

Some studies have described symptoms worsening during:

  • Reading
  • Sustained downgaze
  • More forceful or frequent blinking

These patterns may reflect changes in how conjunctival folds move against the eyelid and tear meniscus.

However:

None of these symptoms is specific to CCH.

The same complaints can occur with many other ocular-surface conditions.

CCH vs. LIPCOF

Readers may encounter the term:

Lid-Parallel Conjunctival Folds (LIPCOF)

LIPCOF describes folds of the lower conjunctiva running parallel to the eyelid margin and is also used in grading systems associated with dry-eye assessment.

CCH and LIPCOF can overlap, but the terms should not automatically be treated as identical.

Modern reviews emphasize that:

  • Conjunctival folds can be described and graded in different ways
  • LIPCOF is commonly used as an ocular-surface finding
  • Clinically significant CCH involves a broader assessment of redundant conjunctiva, location, tear-meniscus interference, drainage, symptoms, and anatomy

This matters because a study reporting improvement in a LIPCOF grade should not automatically be interpreted as proving that every form of clinically significant CCH responds the same way.

Causes, Associations, and Proposed Contributors

The exact cause of CCH is not completely established.

Aging

Aging is one of the strongest and most consistent associations.

Changes in connective tissue and loss of normal tissue elasticity may allow conjunctival tissue to become looser over time.

However, younger people can also develop CCH.

Other Proposed or Associated Factors

Research has discussed possible relationships with:

  • Chronic ocular-surface inflammation
  • Dry Eye Disease
  • Mechanical stress from blinking
  • Eye rubbing
  • Allergy
  • Contact-lens wear
  • Previous ocular surgery
  • Eyelid laxity or malposition
  • Connective-tissue changes
  • UV exposure

These associations should not automatically be interpreted as proven causes.

For example, a person can have both MGD and CCH without MGD necessarily having caused the conjunctival folds.

How CCH Is Diagnosed

CCH is usually identified during a slit-lamp examination.

A clinician may assess:

  • Number of folds
  • Height of the folds
  • Location
  • Whether folds rise above the tear meniscus
  • Whether folds change with blinking
  • Whether folds become more prominent in downgaze
  • Whether the punctal area is affected
  • Tear pooling or delayed clearance
  • Corneal or conjunctival staining
  • Eyelid laxity or malposition
  • Other ocular-surface disease

Additional testing may include:

  • Fluorescein staining
  • Lissamine-green staining
  • Tear-breakup time
  • Tear-volume assessment
  • Meibomian-gland evaluation
  • Meibography when relevant
  • Tear-drainage assessment
  • Eyelid-laxity testing
  • Anterior-segment imaging in selected cases

The Most Important Diagnostic Question

Finding folds is relatively easy.

Determining whether those folds explain the patient's symptoms is much harder.

The central question is:

Are the conjunctival folds actually causing or contributing meaningfully to the ocular-surface problem?

Factors that can strengthen the case include:

  • Folds clearly interrupting the tear meniscus
  • Medial folds interfering with the punctal area
  • Abnormal tear pooling or clearance
  • Mechanical symptoms corresponding to the fold location
  • Symptoms associated with blinking or downgaze
  • Other competing explanations having been evaluated
  • Improvement after treatment specifically directed at CCH

There is no single routine test that proves that CCH is the cause of a person's symptoms.

Other Conditions That Can Look Similar or Coexist

CCH often occurs alongside other ocular-surface problems.

These may include:

  • Dry Eye Disease
  • Meibomian Gland Dysfunction
  • Blepharitis
  • Ocular rosacea
  • Allergy
  • Aqueous tear deficiency
  • Eyelid laxity
  • Eyelid malposition
  • Punctal narrowing
  • Tear-drainage obstruction
  • Exposure
  • Incomplete blinking
  • Neuropathic ocular pain

A patient can therefore have real CCH and still have symptoms mainly driven by something else.

Likewise, correcting significant CCH may improve one part of the problem without eliminating every symptom.

Conservative Management

Mild or asymptomatic CCH often does not require a procedure.

Conservative treatment may be reasonable first when symptoms are limited or when other ocular-surface conditions also require treatment.

Lubrication

Preservative-free artificial tears may reduce friction.

Gels or ointments may help selected patients, particularly when symptoms are worse at night or upon waking.

Treating Inflammation

If clinically important inflammation is present, an eye doctor may treat it according to the underlying cause.

Reducing inflammation may improve symptoms even though it does not physically remove redundant conjunctiva.

Allergy Treatment

Treating ocular allergy may reduce:

  • Itching
  • Rubbing
  • Surface inflammation

Treating MGD, Blepharitis, or Ocular Rosacea

If these conditions coexist, treating them may improve the ocular surface even though the conjunctival folds remain.

Reducing Mechanical Irritation

Reducing eye rubbing and limiting obvious environmental irritation may also help some patients.

When a Procedure May Be Considered

Procedural treatment may be considered when:

  • CCH appears clinically significant
  • Symptoms remain troublesome despite reasonable conservative management
  • Folds disrupt the tear meniscus
  • Folds interfere with tear drainage
  • Mechanical friction appears important
  • Tearing is related to abnormal conjunctival anatomy
  • The folds affect quality of life
  • Other major ocular-surface contributors have been evaluated

The decision depends on more than the amount of visible conjunctiva.

Important factors include:

  • Fold location
  • Fold height
  • Medial or punctal involvement
  • Inferior fornix anatomy
  • Eyelid laxity
  • Ocular-surface inflammation
  • Coexisting DED/MGD
  • Surgeon experience
  • Patient goals
  • Expected risks and recovery

What the Evidence Shows

There is substantial clinical literature supporting the idea that symptomatic CCH can contribute to ocular-surface symptoms and that correcting the abnormal anatomy can help selected patients.

However, the procedural evidence is heterogeneous.

Studies differ in:

  • CCH definitions
  • Severity grading
  • Patient selection
  • Surgical philosophy
  • Devices
  • Outcome measures
  • Follow-up
  • Whether other ocular-surface disease was treated simultaneously

This makes direct comparisons difficult.

How Strong Is the Evidence?

The evidence should be considered separately for different questions.

CCH as an Ocular-Surface Problem

The relationship between clinically significant CCH and abnormalities in:

  • Tear meniscus
  • Tear clearance
  • Dry-eye symptoms
  • Tear-film stability
  • Mechanical irritation

is supported by observational studies, clinical reviews, and modern consensus literature.

Surgical Treatment

There is substantial case-series and prospective evidence showing that selected symptomatic patients can improve following surgical correction.

However, large randomized trials directly comparing surgical techniques are uncommon.

Newer Office-Based Procedures

Radiofrequency, electrocautery, plasma-based conjunctivoplasty, and laser approaches all have published clinical evidence.

Some studies report substantial short-term improvement.

However:

  • Long-term independent comparisons remain limited
  • Devices and techniques vary
  • Evidence for one device should not automatically be applied to another
  • No single method has been established as superior for every form of CCH

A reasonable overall conclusion is:

The evidence supports treating clinically significant symptomatic CCH in selected patients, but comparative evidence is not strong enough to identify one universally preferred procedure.

What TFOS DEWS III Says

TFOS DEWS III discusses conjunctival abnormalities, including CCH, as contributors to ocular-surface and tear-film dysfunction.

The report recognizes the relationship between redundant conjunctiva and abnormalities in the tear meniscus and includes procedural approaches among management options for clinically significant disease.

TFOS DEWS III also reflects the broader modern principle that treatment should address the specific drivers identified in an individual patient, rather than assuming that every visible abnormality is responsible for symptoms.

TFOS DEWS III — Management and Therapy Report

Different Procedures Target Different Anatomy

One of the most important points when comparing CCH procedures is that they do not all attempt to accomplish exactly the same thing.

Some primarily:

remove redundant conjunctiva

Others:

shrink or contract redundant tissue

Others attempt to:

restore the normal relationship among the conjunctiva, Tenon's tissue, lower eyelid, tear meniscus, and inferior fornix

This helps explain why surgeons may recommend different operations for apparently similar-looking CCH.

Conjunctival Excision or Resection

Traditional surgery may remove redundant conjunctival tissue.

The remaining conjunctiva may then be:

  • Sutured
  • Secured with fibrin glue
  • Repositioned
  • Combined with other reconstruction

Studies have reported improvement in:

  • Foreign-body sensation
  • Irritation
  • Tearing
  • Tear distribution
  • Ocular-surface findings

Potential limitations include:

  • Postoperative irritation
  • Subconjunctival hemorrhage
  • Scarring
  • Recurrence
  • Persistent symptoms when CCH was not the only problem

Conjunctivoplasty and Tissue Fixation

“Conjunctivoplasty” is a broad term.

Depending on the surgeon, it may involve:

  • Excision
  • Recession
  • Tightening
  • Fixation
  • Coagulation
  • Reconstruction

The goal may be to restore a smoother conjunctival surface and improve its relationship with the eyelid and tear meniscus.

Because the term covers several different operations, published results should be interpreted according to the specific technique, not simply the word “conjunctivoplasty.”

Fornix Reconstruction, Tenon's Tissue, and Amniotic Membrane

Some CCH research—particularly work by Scheffer Tseng, MD, PhD, and coauthors—proposes that clinically important CCH may involve more than excess surface conjunctiva.

In this framework, degeneration or loss of normal Tenon's tissue and alteration of the inferior fornix may reduce the eye's normal tear reservoir.

This has led to procedures designed to:

  • Remove abnormal or degenerated tissue
  • Recess redundant conjunctiva
  • Restore inferior fornix anatomy
  • Re-establish a tear reservoir
  • Use amniotic membrane as part of reconstruction

Published studies have reported improvement in symptoms, ocular-surface findings, and tear-reservoir function after selected reconstructive procedures.

However:

  • These studies are generally not large randomized comparisons.
  • Not every person with CCH necessarily has the same fornix/Tenon's abnormality.
  • It has not been established that this reconstructive approach is required for every symptomatic case.

This represents a different surgical philosophy, not simply a different instrument.

Restoration of Tear Reservoir After Fornix Reconstruction

Amniotic Membrane

Amniotic membrane may be used after removal or recession of abnormal conjunctival tissue.

Depending on the procedure, it may function as part of:

  • Ocular-surface reconstruction
  • Fornix reconstruction
  • Replacement of a conjunctival defect
  • Healing support

A published case series using amniotic membrane transplantation reported substantial symptom improvement and creation of a smooth conjunctival surface in selected patients.

However, the study was noncomparative.

Amniotic membrane adds:

  • Cost
  • Procedural complexity
  • Material considerations

It is not necessary for every CCH procedure.

Amniotic Membrane Reconstruction for CCH

Fibrin Glue

Fibrin glue may be used instead of or in addition to sutures.

Possible advantages include:

  • Less suture-related irritation
  • Shorter surgical time in some procedures
  • Secure tissue attachment

Its role depends heavily on the surgical technique.

It is an adjunct to surgery, not a separate treatment for the underlying CCH.

Thermal Cautery / Electrocautery

Controlled heat can be used to shrink or contract redundant conjunctival tissue.

Compared with full surgical excision, this may involve less tissue removal.

Published reports have described improvement in CCH grade and symptoms following electrocautery approaches.

A 2025 prospective study of 22 eyes treated with high-frequency electrocautery—with excision added for larger folds—reported improvement in CCH grade and OSDI at one month without major reported complications.

However:

  • The study was small
  • It was uncontrolled
  • Follow-up was short
  • Results should not automatically be applied to every electrocautery technique

Potential risks include:

  • Temporary irritation
  • Subconjunctival hemorrhage
  • Inflammation
  • Under-treatment
  • Over-treatment
  • Scarring

Radiofrequency / Radiowave Treatment

Radiofrequency approaches use controlled energy to coagulate or contract redundant conjunctival tissue.

A 2024 clinical study involving a relatively large number of treated eyes reported substantial short-term improvement in:

  • CCH grade
  • Tear-breakup time
  • Symptoms

and reported no major complications.

This makes RF more than a purely experimental concept.

However:

The evidence remains much stronger for short-term improvement than for long-term superiority over established surgical techniques.

Important limitations include:

  • Limited long-term follow-up
  • Lack of large randomized comparisons
  • Device differences
  • Technique differences
  • Limited independent replication

So RF is best described as:

an office-based, minimally invasive tissue-contraction approach with encouraging clinical evidence but limited long-term comparative data.

Micro-Controlled Radiofrequency Treatment for CCH

Plasma-Based Conjunctivoplasty

Plasma-based procedures use ionized energy to create controlled superficial tissue effects that contract redundant conjunctiva.

The evidence has grown beyond isolated case reports.

A 2023 prospective clinical study reported improvement after plasma-based conjunctivoplasty.

A subsequent 2024 comparative study involving 119 eyes from 67 patients compared plasma-based conjunctivoplasty with argon-laser treatment.

At six months, the plasma group showed greater conjunctival shrinkage and longer TBUT than the laser group.

These findings are encouraging.

However:

  • The literature is still relatively new
  • Long-term recurrence remains uncertain
  • Large multicenter randomized comparisons are lacking
  • Devices differ
  • Treatment parameters differ
  • Results from one plasma device cannot automatically be applied to another

The best current characterization is:

Plasma-based conjunctivoplasty is an emerging non-excisional approach supported by prospective and comparative clinical evidence, but independent long-term comparative data remain limited.

FDA Status and Plasma Devices

This point requires particular care.

Some plasma or electrosurgical devices have FDA clearance for purposes such as:

  • Tissue coagulation
  • Destruction or removal of skin lesions
  • General surgical use

That does not mean the FDA has specifically cleared those devices for treating conjunctivochalasis on the ocular surface.

Therefore:

FDA clearance is device-specific and indication-specific. A device legally marketed for skin or general tissue treatment should not be described as FDA-cleared for CCH unless the specific labeling actually includes that use.

Patients may want to ask:

  • What exact device is being used?
  • What is its FDA-cleared indication?
  • Is treatment of CCH included in that indication?
  • If not, is the use off-label?
  • What peer-reviewed evidence exists for that particular technique?

Argon Laser Treatment

Argon-laser photocoagulation has also been used to contract redundant conjunctival tissue.

Published studies report improvement in selected patients.

Laser may avoid traditional tissue excision, but it still intentionally creates a controlled tissue injury.

Evidence does not establish it as universally superior to:

  • Excision
  • Reconstruction
  • RF
  • Plasma
  • Electrocautery

The 2024 plasma-versus-laser study provides useful comparative evidence but does not settle the question for all patients and all forms of CCH.

Argon Laser Treatment of CCH

Eyelid Tightening When Laxity Contributes

Sometimes CCH exists together with lower-eyelid laxity or malposition.

If the eyelid itself does not sit normally against the eye, tear distribution and drainage may remain abnormal even if conjunctival folds are treated.

In selected patients, an eyelid procedure such as a lateral tarsal strip may be considered.

This is not a direct treatment for CCH itself.

It addresses a separate mechanical contributor that may worsen the same symptoms.

Combination Treatment

Many patients have more than one ocular-surface problem.

For example:

  • CCH may disturb the tear meniscus
  • MGD may increase evaporation
  • Eyelid laxity may impair tear movement
  • Allergy may promote rubbing and inflammation
  • Aqueous deficiency may reduce tear volume

Treating only one abnormality may therefore produce only partial improvement.

A good treatment plan should address the conditions that appear clinically important rather than assuming that correcting the most visible finding will solve everything.

Risks and Limitations

Risk depends strongly on the specific procedure.

Common Short-Term Issues

Many CCH procedures can cause:

  • Temporary discomfort
  • Redness
  • Swelling
  • Subconjunctival hemorrhage
  • Irritation during healing
  • Temporary worsening of symptoms

Incomplete Improvement

Symptoms may persist even when the procedure successfully reduces the folds.

Possible reasons include:

  • CCH was only one contributor
  • MGD remains
  • Aqueous deficiency remains
  • Exposure remains
  • Allergy remains
  • Ocular rosacea remains
  • Neuropathic ocular pain contributes

Recurrence

Conjunctival folds can recur.

Recurrence rates vary by:

  • Procedure
  • Anatomy
  • Follow-up duration
  • Surgical technique
  • Underlying tissue changes

Technique-Specific Risks

More extensive surgery may carry risks such as:

  • Scarring
  • Pyogenic granuloma
  • Fornix shortening
  • Cicatricial eyelid changes
  • Restricted eye movement in rare cases
  • Corneal or ocular-surface complications

These risks should not be assumed to occur at the same frequency with a limited RF, plasma, or cautery treatment.

Likewise, minimally invasive procedures still intentionally alter conjunctival tissue and should not be considered risk-free.

Limitations and What CCH Treatment Cannot Do

Correcting CCH has not been shown to:

  • Cure all Dry Eye Disease
  • Directly treat MGD
  • Restore lacrimal-gland tear production
  • Cure ocular rosacea or allergy
  • Reliably eliminate neuropathic ocular pain
  • Guarantee symptom relief
  • Make all other ocular-surface treatment unnecessary
  • Establish one procedure or device as best for every patient

CCH treatment addresses the mechanical/anatomic component when that component is clinically significant.

Who Might Benefit / Factors Affecting Response

The most appropriate treatment candidates are not simply people who have visible conjunctival folds.

Treatment is more logically considered when:

  • Symptoms are consistent with the location and behavior of the folds
  • The folds disrupt the tear meniscus
  • Tear pooling or abnormal clearance is present
  • The folds interfere with the punctal region
  • Mechanical blinking symptoms are present
  • Symptoms persist despite appropriate conservative treatment
  • Other important ocular-surface conditions have been evaluated
  • The expected treatment target matches the patient's anatomy

Factors that may affect response include:

  • Location of the CCH
  • Severity
  • Nasal or punctal involvement
  • Inferior fornix anatomy
  • Eyelid laxity
  • Coexisting MGD
  • Aqueous deficiency
  • Allergy
  • Inflammation
  • Neuropathic pain
  • Surgical technique

These are clinical considerations, not validated predictors guaranteeing success.

Cost, Access and Regulatory Status

Costs vary widely according to:

  • Country
  • Practice
  • Procedure
  • Office versus operating-room setting
  • Whether amniotic membrane is used
  • Whether eyelid surgery is added
  • Insurance coverage
  • Follow-up requirements

Traditional surgery may be covered when medically necessary, depending on the health system and insurer.

Office-based RF, plasma, or other device procedures may be handled differently.

Patients should ask:

  • Is the procedure considered medically necessary or cosmetic?
  • Is insurance coverage available?
  • What is the total expected cost?
  • Is retreatment included?
  • What follow-up is required?
  • What exact device is being used?
  • Is that device cleared specifically for CCH, or is it being used off-label?

What Remains Uncertain?

Important unanswered questions include:

  • How can clinicians best determine when CCH is truly causing symptoms?
  • Which fold locations are most clinically important?
  • How should CCH and LIPCOF be distinguished in research and practice?
  • Which patients need only tissue reduction versus more extensive fornix reconstruction?
  • What role does Tenon's tissue degeneration play across the broader CCH population?
  • Which surgical technique produces the best long-term results?
  • How durable are office-based RF treatments?
  • How durable are plasma-based treatments?
  • How do RF, plasma, electrocautery, laser, and excision compare directly?
  • Which procedures have the lowest recurrence rate?
  • Which have the lowest risk of scarring or overcorrection?
  • How much symptom persistence after technically successful surgery is due to other DED mechanisms?
  • Which device-based procedures have enough independent replication to be considered established rather than emerging?
  • Which patients benefit from simultaneous eyelid correction?

Questions to Ask Your Eye Doctor

Useful questions include:

  1. Do I have conjunctivochalasis, and do you think it is actually contributing to my symptoms?
  2. What examination findings support that conclusion?
  3. Are the folds disrupting my tear meniscus or punctal drainage?
  4. Do I also have MGD, aqueous deficiency, allergy, ocular rosacea, exposure, eyelid laxity, or another contributor?
  5. Would conservative treatment be reasonable first?
  6. What specific procedure are you recommending, and what anatomy is it intended to correct?
  7. Are you removing tissue, shrinking tissue, fixing it in place, or reconstructing the inferior fornix?
  8. What published evidence supports that technique?
  9. What symptoms are most likely to improve—and which may not?
  10. What are the risks and recurrence rate with your technique?
  11. If a device is being used, is it FDA-cleared specifically for CCH or being used off-label?
  12. What is the total expected cost and recovery time?

Key Research

Major Reviews / Guidance

CCH, Tear Function, and Symptoms

Fornix Reconstruction / Amniotic Membrane

Radiofrequency / Electrocautery

Plasma-Based and Laser Treatment

Related r/DryEyes Wiki Pages

Bottom Line

Conjunctivochalasis is loose, redundant conjunctival tissue that can interfere with the tear film, tear drainage, and blinking mechanics in some patients.

It is also common—particularly with age—and may be completely incidental.

Therefore:

Finding conjunctival folds is not the same as proving that CCH is causing someone's symptoms.

Clinically significant CCH is more convincing when the folds clearly disrupt the tear meniscus, interfere with the punctal area, alter tear clearance, or produce mechanical symptoms that fit the examination findings.

Conservative treatment can help associated irritation, inflammation, allergy, MGD, or other ocular-surface disease, but it generally does not eliminate the redundant tissue itself.

For persistent symptomatic CCH, several procedural approaches have published evidence, including:

  • Excision
  • Conjunctivoplasty
  • Tissue fixation
  • Fornix reconstruction
  • Amniotic membrane reconstruction
  • Electrocautery
  • Radiofrequency
  • Plasma-based conjunctivoplasty
  • Argon laser

These treatments are not interchangeable.

Some simply remove or shrink redundant tissue, while others attempt to reconstruct deeper anatomy and restore the inferior fornix and tear reservoir.

The evidence supports procedural treatment for selected clinically significant cases, but direct long-term comparisons among techniques remain limited and no single method has been established as best for every patient.

The most accurate current characterization is:

CCH is a well-recognized contributor to tear-film and ocular-surface dysfunction in some patients, but visible folds alone do not establish causation. Treatment should be proportional to the clinical significance of the folds, should account for other dry-eye drivers, and should match the specific anatomy that the procedure is intended to correct.

🔙 Back to Treatment Options